Лихорадка Денге у российских туристов, прибывших из Таиланда


Цитировать

Полный текст

Аннотация

Аннотация. В обзоре на примерах завезенных случаев лихорадки Денге проанализированы основные эпидемиологические и клинические аспекты болезни. Даны алгоритмы обследования больных с лихорадкой неясной этиологии, прибывших из тропических стран. На основании обширных данных литературы и международных рекомендаций представлены алгоритмы тактики лечения амбулаторных и стационарных больных лихорадкой Денге. Проанализированы перспективные исследования вакцинопрофилактики лихорадки Денге.

Полный текст

Лихорадка Денге у российских туристов, прибывших из Таиланда. - Аннотация. В обзоре на примерах завезенных случаев лихорадки Денге проанализированы основные эпидемиологические и клинические аспекты болезни. Даны алгоритмы обследования больных с лихорадкой неясной этиологии, прибывших из тропических стран. На основании обширных данных литературы и международных рекомендаций представлены алгоритмы тактики лечения амбулаторных и стационарных больных лихорадкой Денге. Проанализированы перспективные исследования вакцинопрофилактики лихорадки Денге.
×

Об авторах

И В Шестакова

МГМСУ им. А.И. Евдокимова

Email: shes.irin@mtu-net.ru

Н Д Ющук

МГМСУ им. А.И. Евдокимова

Email: shes.irin@mtu-net.ru

И Б Акинфиев

МГМСУ им. А.И. Евдокимова

Т И Попова

Инфекционная клиническая больница №2, Москва

Т В Сергеева

Инфекционная клиническая больница №2, Москва

Е Т Вдовина

Инфекционная клиническая больница №2, Москва

Список литературы

  1. Информационный бюллетень ВОЗ №117, декабрь 2012 г. Доступно на http://www.who.int/ru/
  2. Guzman M.G., Halstead S.B., Artsob H. et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 20: S7-S16.
  3. Готовность к чрезвычайным ситуациям и реагирование на них. Лихорадка денге на Мадейре. ВОЗ 17.10.2012.
  4. Протокол совещания специалистов, осуществляющих эпидемиологический надзор за инфекционными и паразитарными болезнями, 16 мая 2013 г. Москва. Доступно на http://rospotrebnadzor.ru/.
  5. Clyde K., Kyle J.L., Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 2006; 20: 11418-11431.
  6. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 20: 480-496.
  7. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: World Health Organization 1997; 84.
  8. Sierra B., Kouri G., Guzman M.G. Race: a risk factor for dengue hemorrhagic fever. Arch Virology 2007; 152 (3): 533-542.
  9. Guzman A., Isturiz R.E. Update on the global spread of dengue. Int J Antimicrob Agents 2010; 20 (Suppl 1): S40-S42.
  10. Kroeger A. Effective control of dengue vectors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster randomized trials. Br Med J 2006; 332: 1247-1252.
  11. Global strategic framework for integrated vector management. Geneva, World Health Organization, 2004 (Document WHO/CDS/CPE/2004.10, available at: http://whqlibdoc.who.int/hq/2004/WHO_CDS_CPE_PVC_2004_10.pdf; accessed October 2008.
  12. Lei H.Y., Yeh T.M., Liu H.S. et al. Immunopathogenesis of dengue virus infection. J Biomed Sci 2001; 20: 377-388.
  13. Green S., Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 20: 429-436.
  14. Whitehorn J., Simmons C.P. The pathogenesis of dengue. Vaccine. 2011; 20: 7221-7228.
  15. Yacoub S., Mongkolsapaya J., Screaton G. The pathogenesis of dengue. Curr Opin Infect Dis 2013; 20: 284-289.
  16. Pandey B.D., Morita K., Hasebe F. et al. Molecular evolution, distribution and genetic relationship among the dengue 2 viruses isolated from different clinical severity. Southeast Asian J Trop Med Public Health 2000; 20: 266-272.
  17. Vaughn D.W., Green S., Kalayanarooj S. et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 20: 2-9.
  18. Cologna R., Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003; 20: 3929-3938.
  19. Leitmeyer K.C., Vaughn D.W., Watts D.M. et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999; 20: 4738-4747.
  20. de Borba L., Strottmann D.M., de Noronha L. et al. Synergistic interactions between the NS3(hel) and E proteins contribute to the virulence of dengue virus type 1. PLoS Negl Trop Dis 2012; 20: e1624.
  21. Perng G.C., Lei H.Y., Lin Y.S., Chokephaibulkit K. Dengue vaccines: challenge and confrontation. World J Vaccin 2011; 20: 109-130.
  22. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 20: 421-467.
  23. Ubol S., Phuklia W., Kalayanarooj S., Modhiran N. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 2010; 20: 923-935.
  24. Ubol S., Halstead S.B. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol 2010; 20: 1829-1835.
  25. Halstead S.B., Mahalingam S., Marovich M.A. et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 2010; 20: 712-722.
  26. Rothman A.L. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011; 20: 532-543.
  27. Espada-Murao L.A., Morita K. Dengue and soluble mediators of the innate immune system. Trop Med Health 2011; 20: 53-62.
  28. Wan S.W., Lin C.F., Yeh T.M. et al. Autoimmunity in dengue pathogenesis. J Formos Med Assoc 2013; 20: 3-11.
  29. Halstead S.B., Heinz F.X. Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine 2005; 23 (7): 849-856.
  30. Avirutnan P., Malasit P., Seliger B. et al. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 1998; 161: 6338-6346.
  31. Cardier J.E. Proinflammatory factors present in sera from patients with acute dengue infection induce activation and apoptosis of human microvascular endothelial cells: possible role of TNF-alpha in endothelial cell damage in dengue. Cytokine 2005; 30 (6): 359-365.
  32. Lin Y.S., Yeh T.M., Lin C.F. et al. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Exp Biol Med (Maywood) 2011; 20: 515-5234.
  33. Chuang Y.C., Lin Y.S., Liu C.C. et al. Factors contributing to the disturbance of coagulation and fibrinolysis in dengue virus infection. J Formos Med Assoc 2013; 20: 12-17.
  34. Геморрагическая лихорадка денге: диагностика и лечение. ВОЗ 1988; 74.
  35. Rigau-Perez J.G., Clark G.G., Gubler D.J. et al. Dengue and dengue haemorrhagic fever. Lancet 1998; 352: 971-977.
  36. Balmaseda A., Hammond S.N., Pérez M.A. et al. Assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am J Tropical Med Hygi 2005; 73: 1059-1062.
  37. Bandyopadhyay S., Lum L.C., Kroeger A. Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. Trop Med Int Health 2006; 11 (8):1238-1255.
  38. Srikiatkhachorn A., Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol 2009; 20: 67-82.
  39. Martina B.E., Koraka P., Osterhaus A.D. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 2009; 20: 564-581.
  40. Murphy B.R., Whitehead S.S. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011; 20: 587-619.
  41. Jhamb R., Kumar A., Ranga G.S., Rathi N. Unusual manifestations in dengue outbreak 2009, Delhi, India. J Commun Dis 2010; 42 (4): 255-261.
  42. Kalayanarooj S. Dengue classification: current WHO vs. the newly suggested classification for better clinical application? J Med Assoc Thai 2011; 94 (Suppl 3): S74-84.
  43. Barniol J., Gaczkowski R., Barbato E.V. et al. Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries. BMC Infect Dis 2011; 20: 106.
  44. Международные медико-санитарные правила. ВОЗ 15.06.2007.
  45. СП 3.4.2318-08 "Санитарная охрана территории Российской Федерации".
  46. Руководство по сбору клинических образцов во время полевых расследований вспышек. WHO/CDS/CSR/EDC/2000.4
  47. МУ 3.4.3008-12 "Порядок эпидемиологической и лабораторной диагностики особо опасных, "новых" и "возвращающихся" инфекционных болезней" М 2012; 57.
  48. Cao X.T., Ngo T.N., Wills B. et al. Evaluation of the World Health Organization standard tourniquet test in the diagnosis of dengue infection in Vietnam. Tropical Med Intern Health 2002; 7: 125-132.
  49. Global strategy for dengue prevention and control 2012-2020. World Health Organization 2012; 43.
  50. Dengue diagnostics: proceedings of a joint TDR/WHO and PDVI workshop: 4-6 October 2004, Geneva, Switzerland. Pediatric Dengue Vaccine Initiative; UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. TDR/IRM/DIAG/DEN/05.1.
  51. Shu P.Y. Comparison of a capture immunoglobulin M (IgM) and IgG ELISA and non-structural protein NS1 serotype-specific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin Diagn Lab Immunol 2003; 10: 622-630.
  52. Falconar A.K., de Plata E., Romero-Vivas C.M. Altered enzyme-linked immunosorbent assay immunoglobulin M (IgM)/IgG optical density ratios can correctly classify all primary or secondary dengue virus infections 1 day after the onset of symptoms, when all of the viruses can be isolated. Clin Vaccine Immunol 2006; 13: 1044-1051.
  53. Martinez E. Preventing deaths from dengue: a space and challenge for primary health care. Pan Am J Public Health 2006; 20: 60-74.
  54. Dellinger R.P., Levy M.M., Carlet J.M. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Med 2008; 36: 296-327.
  55. Suaya J., Shepard D.S., Siqueira J.B. et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Tropical Med Hyg 2009; 80: 846-855.
  56. Suaya J., Shepard D.S., Beatty M.E. Dengue: burden of disease and costs of illness [working paper 3.2]. In: Report of the Scientific Working Group meeting on Dengue, Geneva, 1-5 October 2006. Geneva, World Health Organization, Special Programmer for Research and Training in Tropical Diseases 2007: 35-49.
  57. Parks W., Lloyd L.S. Planning social mobilization and communication for dengue fever prevention and control: a step-by-step guide. Geneva: World Health Organization, 2004 (available at: http://www.who.int/tdr/publications/publications/pdf/planning_dengue.pdf; accessed October 2008)].
  58. Schul W., Liu W., Xu H.Y. et al. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007; 195: 665-674.
  59. Patkar C.G., Kuhn R.J. Development of novel antivirals against flaviviruses. Novartis Foundation Symposium 2006; 277: 41-52.
  60. Keller T.H., Chen Y.L., Knox J.E. et al. Finding new medicines for flaviviral targets. Novartis Foundation Symposium 2006; 277: 102-114.
  61. Yauch L.E., Zellweger R.M., Kotturi M.F. et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009; 20: 4865-4873.
  62. Gil L., Lopez C., Lazo L. et al. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol 2009; 20: 1175-1183.
  63. Gil L., Lopez C., Blanco A. et al. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 2009; 20: 23-30.
  64. Zompi S., Santich B.H., Beatty P.R., Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 2012; 20: 404-416.
  65. Zompi S., Montoya M., Pohl М.О. et al. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis 2012; 20: e1568.
  66. Innis B.L., Eckels K.H., Kraiselburd E. et al. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis 1998; 158: 876-880.
  67. Hombach J., Cardosa M.J., Sabchareon A. et al. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 2007; 25: 4130-4139.
  68. Wan S.W., Lin C.F., Wang S. et al. Current progress in dengue vaccines. J Biomed Sci 2013; 20: 37.
  69. Guy B., Barrere B., Malinowski C. et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29: 7229-7241.
  70. Lang J. et al. Toward a tetravalent dengue vaccine in Brazil, Tropical Medicine meeting, Iguacu Falls, March 2010.
  71. Coller B.A., Clements D.E. Dengue vaccines: progress and challenges. Cur Opin Immunol 2011; 23: 391-398.
  72. Ng C.Y., Gu F., Phong W.Y. et al. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res 2007; 76 (3): 222-231.
  73. Schmitz J., Roehrig J., Barrett A., Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011; 29: 7276-7284.
  74. Chanthavanich P.C. Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Tropical Med Hyg 2006; 75: 26-28.
  75. Dengue guidelines for diagnosis, treatment, prevention and control: new edition World Health Organization. WHO/HTM/NTD/DEN/2009.1.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2013

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Адрес издателя

  • 127055, г. Москва, Алабяна ул., 13, корп.1

Адрес редакции

  • 127055, г. Москва, Алабяна ул., 13, корп.1

По вопросам публикаций

  • +7 (926) 905-41-26
  • editor@ter-arkhiv.ru

По вопросам рекламы

  • +7 (495) 098-03-59

 

  


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах